Login to Your Account



Genentech, AC Immune in $421M Alzheimer's Deal

By Cormac Sheridan
Staff Writer

Tuesday, June 19, 2012
Genentech, a member of the Roche Group, exhibited its evident enthusiasm for AC Immune SA's pipeline of antibodies in development for Alzheimer's disease, by in-licensing the company's preclinical tau-targeting program in a deal potentially worth upward of CHF400 million (US$421 million) in up-front plus research, development and sales-associated milestone payments.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription